Kestra Medical Technologies, Ltd. Common Stock (KMTS) Stock Price
KMTSStock
$27.24+17.06%52W
Market Cap$1.62B
P/E—
PEG Ratio—
Div yield—
Beta1.51
KMTS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)28.09%
Price vs S&P 500 (4W)11.30%
VGM Score60.86
KMTS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.63 | -$0.46 | +26.69%(+$0.17) | |
| Q1 2026 | -$0.58 | -$0.49 | +15.76%(+$0.09) | |
| Q4 2025 | -$0.60 | -$0.40 | +32.63%(+$0.20) | |
| Q3 2025 | -$0.56 | -$0.45 | +19.77%(+$0.11) | |
| Q2 2025 | -$0.78 | -$0.36 | +53.83%(+$0.42) |
KMTS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.31
4.31
4.31
4.29
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
KMTSKestra Medical Technologies, Ltd. Common Stock | F | A | B | 15.2x | — | 53.9% | -140.4% | $27.24 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Kestra Medical Technologies, Ltd. Common Stock
Kestra Medical Technologies is a commercial-stage company developing wearable medical devices and digital healthcare solutions for cardiovascular disease management. Its Cardiac Recovery System platform integrates monitoring, therapy, digital health, and patient support into a unified solution centered on the ASSURE WCD, a wearable cardioverter defibrillator designed to prevent sudden cardiac arrest in high-risk patients. The company targets a significant clinical need by combining advanced wearable technology with connected digital services for cardiac care.